

Title	Cost-effectiveness of cerebrospinal biomarkers for the diagnosis of Alzheimer's disease
Authors	Lee, Spencer A. W.;Sposato, Luciano A.;Hachinski, Vladimir;Cipriano, Lauren E.
Publication date	2017-03-16
Original Citation	Lee, S. A. W., Sposato, L. A., Hachinski, V. and Cipriano, L. E. (2017) 'Cost-effectiveness of cerebrospinal biomarkers for the diagnosis of Alzheimer's disease', <i>Alzheimer's Research and Therapy</i> , 9 (18), pp. 1-14. doi:10.1186/s13195-017-0243-0
Type of publication	Article (peer-reviewed)
Link to publisher's version	10.1186/s13195-017-0243-0
Rights	© 2017, the Authors. Open Access. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. - https://creativecommons.org/licenses/by/4.0/
Download date	2025-03-21 23:17:55
Item downloaded from	https://hdl.handle.net/10468/3867



UCC

University College Cork, Ireland
Coláiste na hOllscoile Corcaigh

Cost effectiveness of cerebrospinal biomarkers for Alzheimer’s diagnosis: Supplementary Material

Lee SAW, Sposato LA, Hachinski V, Cipriano LE

1. SUPPLEMENTAL METHODS

1.1 Alzheimer’s disease transition probability calculations

Spackman et al. estimated the probability of transitions between Alzheimer’s disease health states using the Uniform data set from the National Alzheimer’s Coordinating Center (NACC) in which some patients in each health state were receiving treatment [1]. Our model separately included age-specific mortality adjusted for disease severity, explicitly modeled the effectiveness of disease-modifying treatments, and explicitly modeled living in a long-term care facility (LTCF) accounting for different rates of treatment use among patients in LTCFs. We, therefore, sought to use the transition probabilities estimated by Spackman et al. to estimate treatment-stratified transition probabilities conditional on survival. We briefly explain the steps we took and the assumptions we made:

The following table is reproduced from Spackman et al. and presents the annual probability of transitions between states [1]:

Transition from	Transition to			
	Mild AD	Moderate AD	Severe AD	Dead
Mild AD	77.4%	15.8%	1.3%	5.5%
Moderate AD	7.0%	50.1%	21.4%	21.5%
Severe AD	0.2%	2.7%	49.1%	48.0%
Dead	0%	0%	0%	100.0%

First, we calculated the transition probabilities conditional on survival using the formula:

$$\text{Probability of transition from state A to state B conditional on survival} = \frac{\text{Probability of transition from state A to state B}}{\text{Probability of survival from state A}}$$

For example, the probability of transitioning from Mild AD to Moderate AD (conditional on survival) is $0.158/(1-0.055) = 0.1672$.

The following table presents the transition probabilities conditional on survival:

Transition from	Transition to		
	Mild AD	Moderate AD	Severe AD
Mild AD	81.90%	16.72%	1.38%
Moderate AD	8.92%	63.82%	27.26%
Severe AD	0.38%	5.19%	94.42%

Spackman et al. also reported the proportion of the population receiving AD treatment stratified by disease severity [1]:

	Receiving AD treatment
Mild AD	67.95%
Moderate AD	79.85%
Severe AD	66.51%

Using the average annual transition probability between states, we calculated the annual transition rate using the formula:

$$\text{Annual Rate} = -\text{LN}(1 - \text{Annual Transition Probability})$$

The following table presents the annual transition rates between health states, conditional on survival, per 100,000 person years:

Transition from	Transition to		
	Mild AD	Moderate AD	Severe AD
Mild AD		18,296	1,385
Moderate AD	9,340		31,829
Severe AD	385	5,332	

We do not calculate or present the annual rate of remaining in the same health state as we will calculate the transition probability for remaining as one minus the probabilities of transitioning to other states.

Consistent with a previous model-based analyses of AD, we assumed that AD treatment reduced the transition rate from mild to moderate AD with a hazard ratio of 0.50 and increased the transition rate from moderate to mild AD with a hazard ratio of 2.36 [2].

Using these assumptions for the influence of treatment on transition rates and the proportion of individuals receiving treatment, we calculated the annual transition rates stratified by whether the person was receiving AD treatment using the formula:

$$\text{Average Rate} = \frac{(\text{Proportion not receiving AD treatment} \times \text{Transition rate in AD patients not receiving AD treatment}) + (\text{Proportion receiving AD treatment} \times \text{Transition rate in AD patients not receiving AD treatment} \times \text{Hazard ratio for transition rate in patients receiving treatment compared to those who are not receiving treatment})}{1}$$

We can rearrange this formula for the single unknown value, the transition rate in AD patients not receiving AD treatment:

$$\text{Transition rate in AD patients not receiving AD treatment} = \frac{\text{Average Rate}}{(\text{Proportion not receiving AD treatment} + (\text{Proportion receiving AD treatment} \times \text{Hazard ratio for transition rate in patients receiving treatment compared to those who are not receiving treatment}))}$$

An example calculation for the transition from Mild AD to Moderate AD is:

$$\text{Transition rate in AD patients not receiving AD treatment} = \frac{18296}{((1-67.95\%) + (67.95\% \times 0.5))} = 27,710$$

This resulted in calculating two transition rate matrices: one for patients who are not receiving treatment and one for patients who are receiving AD treatment.

Transition rates per 100,000 person years for patients not receiving treatment:

Transition from	Transition to		
	Mild AD	Moderate AD	Severe AD
Mild AD		27,710	1,385
Moderate AD	4,478		31,829
Severe AD	385	5,332	

Transition rates per 100,000 person years for patients receiving treatment:

Transition from	Transition to		
	Mild AD	Moderate AD	Severe AD
Mild AD		13,855	1,385
Moderate AD	10,567		31,829
Severe AD	385	5,332	

Finally, we converted these to monthly transition probabilities using the formula:

$$\text{Monthly transition probability} = 1 - \text{EXP}(-\text{Annual rate}/12 \text{ months per year})$$

Monthly transition probabilities for patients not receiving treatment:

Transition from	Transition to		
	Mild AD	Moderate AD	Severe AD
Mild AD	97.60%	2.28%	0.12%
Moderate AD	0.37%	97.01%	2.62%
Severe AD	0.03%	0.44%	99.52%

Monthly transition probabilities for patients receiving treatment:

Transition from	Transition to		
	Mild AD	Moderate AD	Severe AD
Mild AD	98.74%	1.15%	0.12%
Moderate AD	0.88%	96.51%	2.62%
Severe AD	0.03%	0.44%	99.52%

We followed a similar set of steps to calculate treatment-stratified transition probabilities for the transition from residing in the community to residing in a LTCF.

Spackman et al. reported the average annual probability of transition from the community to a LTCF such as nursing homes as presented in the following table [1]:

	Annual probability of transition to LTCF
Mild AD	0.012
Moderate AD	0.034
Severe AD	0.066

Beusterien et al. (2004) found that individuals not receiving acetylcholinesterase inhibitors (AChEI) for AD had a hazard ratio of 2.7 (95%CI 1.8-4.0) for transition to a nursing home compared to individuals on acetylcholinesterase inhibitor treatment using a retrospective analysis of a large US medical claims database including more than 5000 patients [3]. These findings are consistent with other studies, which have also found that acetylcholinesterase inhibitor treatment delays nursing home placement [4–6].

Following a similar procedure to the one we described above, we used the average annual transition probability for transition from community to LTCF, the proportion of individuals receiving treatment, and the influence of treatment on the transition to calculate the annual rate of transition to a LTCF stratified by treatment status using the formula:

$$\begin{aligned}
 \text{Average Rate} = & \frac{(\text{Proportion receiving AD treatment} \times \text{Transition rate from the community to LTCF in AD patients receiving AD treatment})}{+} \\
 & (\text{Proportion not receiving AD treatment} \times \text{Transition rate from the community to LTCF in AD patients receiving AD treatment} \times \text{Hazard ratio for the transition rate to LTCF for patients not receiving treatment compared to those who are receiving treatment})
 \end{aligned}$$

Rearranging this formula for the single unknown value (the transition rate to LTCF in AD patients receiving AD treatment) results in:

$$\begin{array}{l}
 \text{Transition rate} \\
 \text{from the} \\
 \text{community to} \\
 \text{LTCF in AD} \\
 \text{patients} \\
 \text{receiving AD} \\
 \text{treatment}
 \end{array}
 = \frac{\text{Average Rate}}{\text{(Proportion receiving AD treatment + Proportion not receiving AD treatment x Hazard ratio for transition to LTCF for patients not receiving treatment compared to those who are receiving treatment)}}$$

Rates (per 100,000 person years) for transition from residing in the community to residing in a LTCF for the overall population, patients not receiving treatment, and those who are receiving treatment stratified by disease severity:

	Annual rates (per 100,000 person years)		
	Average annual rate of transition to LTCF	Annual rate of transition to LTCF in patients not on AD treatment	Annual rate of transition to LTCF in patients on AD treatment
Mild AD	1,207	2,110	781
Moderate AD	3,459	6,957	2,577
Severe AD	6,828	11,747	4,351

We then converted the transition rates into monthly transition probabilities, shown in the following table:

	Monthly probability of transition from residing in the community to residing in a LTCF	
	Not on AD treatment	On AD treatment
Mild AD	0.18%	0.07%
Moderate AD	0.58%	0.21%
Severe AD	0.97%	0.36%

1.2 Cost of AD stratified by disease severity and location (community dwelling or living in a long-term care facility)

Inpatient costs: Inpatient costs were calculated using common diagnoses for patient visits grouped by Diagnosis-Related Group (DRG) found in the Health Care Cost and Utilization Project database (HCUP). The Medicare cost by DRG was multiplied by the percent of hospitalized AD patients per specific DRG to get the average annual Inpatient cost per capita.

Outpatient costs: Outpatient costs were estimated based on a study from Zhao *et al.* (2004) that compared annual health care costs of AD patients to demographically matched patients in community and hospital settings [7].

Emergency care costs: Emergency costs by Alzheimer's severity were calculated from the estimated emergency cost per visit and the proportion of patients within the state that required an emergency visit. Emergency costs were estimated using a study from Fillenbaum *et al* [8]. In this study, the authors calculated probability of at least one visit, frequency of visits, length of stay, and Medicare costs of hospitalization for 428 AD patients from the CERAD database. The proportion of patients within each disease state incurring emergency costs were estimated using a study by Gustavsson *et al.* that conducted interviews with 1222 patients from multinational AD patient cohort and stratified the results based on location of care (community or LTCF) and disease severity [9].

Unpaid caregiving: Informal care costs were calculated based on the average home care worker wage in the United States and multiplied by the estimated home care hours specific to disease severity. Although families continue to provide informal caregiving after patients move into long-term care facilities, additional informal costs were not counted for these patients. We assumed that the full cost of caregiving is accounted for in the cost of a LTCF even if all of the care is not provided by the facility. For example, family members may provide assistance with feeding a disabled patient but this task would be performed by a paid caregiver if the family member were not available and so the cost of doing so is already incorporated into the cost of the long-term care facility.

A complete breakdown of the severity-specific costs of AD care is presented in **Table S1**.

Table S1 – Annual AD-severity specific cost breakdown (US\$)

Cost category	Community dwelling			Long term care facility dwelling			Sources
	Mild	Moderate	Severe	Mild	Moderate	Severe	
Inpatient	6,995	6,995	6,995	6,995	6,995	6,995	[8,10,11]
Outpatient	2,813	2,813	2,813	2,813	2,813	2,813	[7]
<i>Emergency care</i>							
Cost per visit	500	500	500	500	500	500	[8]
Proportion of population that use emergency care	2.9%	2.5%	2.1%	12.7%	12.7%	7.8%	[9]
Average cost of emergency care	15	13	11	64	64	39.00	
<i>Unpaid caregiving</i>							
Caregiver hourly wage	21	21	21	N/A	N/A	N/A	[12]
Home care hours (hrs/week)	13.1	22.0	46.1	N/A	N/A	N/A	[13]
Average annual cost of unpaid caregiving	14,305	24,024	50,341	N/A	N/A	N/A	
Total:	24,128	33,845	60,160	9,872	9,872	9,847	


1.3 Probability distributions for probabilistic sensitivity analysis

Probability distributions were assigned to all model inputs for probabilistic sensitivity analysis (**Table S2**). In most cases, probabilities and utility weights are modeled using Beta distributions, rates and costs are modeled using Normal distributions, and when the uncertainty around a parameter was highly skewed (such as for a hazard ratio), it was modeled using a Gamma distribution. A multivariate Normal distribution was used to simulate the joint distribution of biomarker test performance (described in detail below).

Distribution parameters were selected to maintain the same average value as the base case and to have approximately 95% confidence intervals based on the range used in the deterministic sensitivity analysis.

In some cases, we imposed additional rules to ensure logical rank ordering of randomly drawn values. For example, the quality-of-life utility weight with severe AD must be less than the utility weight with moderate AD which also must be less than the utility weight with mild AD.

Uncertainty in the proportion of patients without AD who will be correctly identified as having an alternative diagnosis (and not having AD) after MR causes the uncertainty in the pre-test prevalence of AD in our patient cohort to be right skewed. Therefore, we modeled it using a gamma distribution:



Developing a joint probability distribution for test accuracy

We used a multivariate Normal distribution in order to maintain a negative correlation between the sensitivity and specificity of the biomarker in probabilistic analysis. We used simulation to replicate the average values and the 95% confidence intervals reported in Bouwman et al. [14] using simple rules. Using the covariance matrix estimated by our simulation, we then assumed a multivariate Normal distribution using the base case values as the mean for each input:

Covariance matrix:

	sensitivity	specificity
sensitivity	0.00661	(0.00026)
specificity	(0.00026)	0.00064

The correlation coefficient between the sensitivity and specificity of the biomarker test was therefore -0.13 .

Table S2 – Base case inputs, ranges for sensitivity analysis, and sources.

Parameter	Base case	Distribution for PSA*
Patient population		
Start age (years)	65	<i>Not varied in PSA</i>
Proportion of referred population with Alzheimer’s Disease (AD) (%)	12.7	<i>See Supplementary Methods Section 1.3</i>
<i>Initial AD severity distribution (%)</i>		
Mild	70	Beta(70, 30)**
Moderate	28	Beta(28, 78)**
Severe	2	Beta(2, 98)**
Diagnosis		
<u>Diagnostic Test Accuracy</u>		
Biomarker analysis (BM)		
Sensitivity	0.698	<i>See Supplementary Methods Section 1.3</i>
Specificity	0.941	<i>See Supplementary Methods Section 1.3</i>
<u>Costs</u>		
BM	463	Normal(356, 100)
<u>Reduction in quality of life from test encounter and invasiveness</u>		
BM	-0.008	-Beta(1, 125)
AD natural history model		
<u>Mortality</u>		
<i>Hazard ratios for AD-specific mortality</i>		
Mild	2.92	Normal(2.92, 0.29)
Moderate	3.85	Normal(3.85, 0.46)
Severe	9.52	Normal(9.52, 1.5)
<u>Disease progression without AD treatment</u> (annual rate per 100,000)		
From Mild		
To Moderate	27,710	Normal(27710, 1386)
To Severe	1,385	Normal(1385, 69)
From Moderate		
To Mild	4,478	Normal(4478, 224)
To Severe	31,829	Normal(31829, 1591)
From Severe		
To Mild	385	Normal(385, 19)
To Moderate	5,332	Normal(5332, 267)
<u>Transition to Long Term Care Facility Care</u> (annual rate per 100,000)		
From Mild	2,110	Normal(2110, 805)
From Moderate	6,957	Normal(6957, 2728)
From Severe	11,747	Normal(11747, 4624)

AD Treatment

Treatment uptake and adherence

Treatment initiation

Donepezil, at diagnosis	0.45	Beta(16.4,20)
Memantine, at transition to severe AD (with diagnosis)	0.36	80% of donepezil

Treatment discontinuation (annual rate per 100,000)

Donepezil, community-dwelling	28,768	Normal(22047, 9116)
Donepezil, facility-dwelling	62,362	Normal(62362, 7992)
Memantine	28,768	Normal(22047, 5640)

Treatment re-initiation after quitting (annual rate per 100,000)

Donepezil	33,142	Normal(33142, 5018)
Memantine	22,314	Normal(22314, 2240)

Treatment effectiveness

Donepezil (hazard ratios)

Transition from mild to moderate	0.5	Gamma(5, 0.1)
Transition from moderate to mild	2.36	Gamma(4.5, 0.5)
Transition from community to long-term care facility	0.37	1/Gamma(15, 0.18)

Memantine

Incremental utility (annualized)	0.051	Beta(5.1, 94.9)
Hazard ratio, transition from community to long-term care facility	0.37	1/Gamma(15, 0.18)

Costs (2013 US\$)

Age Specific Baseline Costs

Base case value × Normal(1, 0.1)

Annual incremental costs by disease-severity (including costs of informal caregiving)

Community dwelling

Patients without AD	24,128	Normal(24127, 1428)
Mild AD	24,128	Normal(24127, 1428)
Moderate AD	33,845	Normal(33845, 2328)
Severe AD	60,160	Normal(60160, 4813)

Long-term care facility dwelling

Facility Cost	83,950	Normal(83950, 5525)
Patients without AD	9,872	
Mild AD	9,872	Normal(9872, 426)
Moderate AD	9,872	Normal(9872, 426)
Severe AD	9,847	Normal(9842, 426)

Medication (annual)

Donepezil, 10 mg/day	2,473	Normal(2473, 907)
Memantine, 10 mg/day	3,192	Normal(3240, 1380)

Age-specific annual health care costs in the year of death

<90 years	35,158	Normal(35,158, 5000)
> 90 years	25,455	Normal(25455, 3000)

Utilities

Age-specific weights

60-64 years	0.83	Beta(415, 86)
65-69 years	0.82	MIN(Utility for age 60-64, Beta(412, 89))
70-74 years	0.81	MIN(Utility for age 65-69, Beta(406, 95))
75-79 years	0.79	MIN(Utility for age 70-74, Beta(395, 105))
>79 years	0.74	MIN(Utility for age 75-79, Beta(316, 84))

Health-state specific weights

Community dwelling

Patients without AD	0.68	Beta(34, 16)
Mild AD	0.68	Beta(34, 16)
Moderate AD	0.54	MIN(Utility for Mild AD, Beta(27, 23))
Severe AD	0.37	MIN(Utility for Moderate AD, Beta(18.5, 31.5))

Long-term care facility dwelling

Patients without AD	0.71	Beta(35.5, 14.5)
Mild AD	0.71	Beta(35.5, 14.5)
Moderate AD	0.48	MIN(Utility for Mild AD in a LTCF, Beta(24, 26))
Severe AD	0.31	MIN(Utility for Moderate AD in a LTCF, Beta(15.5, 34.5))

* Beta distributions are parameterized Beta(a, b) where the mean is calculated $a/(a+b)$. Normal distributions are parameterized Normal(mean, standard deviation). Gamma distributions are parameterized Gamma(shape, scale) where the mean is calculated as shape multiplied by scale. MIN(x, y) indicates that the minimum of two values was taken. For example, for the age-specific utility weight for age 65-69 is MIN(Utility for age 60-64, Beta(412, 89)) which ensures that the age-specific utility for age 65-69 cannot be greater than the age specific utility weight for age 60-64.

** Re-scaled to ensure the sum of the three probabilities is one.

2. SUPPLEMENTAL RESULTS

Table S3 – Deterministic Sensitivity Analysis. The incremental cost and incremental QALYs of CSF Biomarker analysis compared to no biomarker and the preferred alternative at willingness-to-pay thresholds of \$50,000 per QALY-gained and \$100,000 per QALY-gained. Negative incremental values indicate that no biomarker analysis costs more and/or provided more QALYs than the biomarker analysis.*

Scenario	BM compared to No BM		Preferred alternative at willingness to pay threshold	
	Incremental Costs	Incremental QALYs	\$50,000 /QALY-gained	\$100,000 /QALY-gained
Base Case	165	0.015	BM	BM
<u>Age</u>				
Younger, Age 60	-269	0.020	BM	BM
Older, Age 75	653	0.005	Do nothing	Do nothing
Older, Age 80	730	0.000	Do nothing	Do nothing
<u>AD Severity distribution at diagnosis</u>				
Shifted to less severe (Mild = .78; Moderate = .21; Severe = .01)	144	0.016	BM	BM
Shifted to more severe diseases [4] (Mild = .61; Moderate = .34; Severe = .04)	191	0.014	BM	BM
<u>Biomarker test accuracy</u>				
Very low accuracy and moderately high prevalence: (SN=54%, SP=84%, Prevalence=15%)	1,161	0.013	Do nothing	BM
Very low: (SN=54%, SP=84%)	1,326	0.010	Do nothing	Do nothing
Low: (SN=54%, SP=89%)	870	0.010	Do nothing	BM
Moderately low: (SN=62%, SP=92%)	518	0.012	BM	BM
Moderately high: (SN=78%, SP=96%)	-130	0.018	BM	BM
High: (SN=86%, SP=98%)	-426	0.020	BM	BM

<u>BM test cost</u>				
Low cost: (\$250)	-48	0.015	BM	BM
High cost: (\$600)	302	0.015	BM	BM
<u>BM quality of life decrement</u>				
Low: (no decrement)	165	0.023	BM	BM
High: (-0.02)	165	0.003	BM	BM
<u>Treatment</u>				
Treatment decreases moderate to severe transition	299	0.016	BM	BM
All patients with AD diagnosis initiate treatment	-141	0.023	BM	BM
High treatment uptake (56%)	104	0.017	BM	BM
Low treatment uptake (27%)	265	0.012	BM	BM
Low treatment uptake and poor adherence	281	0.011	BM	BM
Best case scenario: high uptake, high adherence, low cost and high effectiveness (utility benefit and impact on transition rates)	-852	0.059	BM	BM
Worst case scenario: low uptake, poor adherence, high cost and low effectiveness	1356	-0.007	Do nothing	Do nothing
<u>Discontinuation Rate**</u>				
High (% per year)	191	0.013	BM	BM
Low (% per year)	82	0.022	BM	BM
No Discontinuation	206	0.029	BM	BM
<u>Proportion of false negative diagnoses corrected when patients' disease progresses</u>				
50%	314	0.011	BM	BM
75%	386	0.009	BM	BM
100%	456	0.007	Do nothing	BM
<u>Mortality</u>				
Low for all severity levels	-270	0.017	BM	BM
High for all severity levels	509	0.013	BM	BM
<u>AD disease progression</u>				
No backwards transitions	379	0.011	BM	BM
10% slower disease progression	140	0.015	BM	BM
10% faster disease progression	186	0.015	BM	BM

Severity specific quality of life

Low for all AD states	165	0.009	BM	BM
High for all AD states	165	0.014	BM	BM

Caregiving and long term care facility (LTCF)

High caregiving costs	325	0.015	BM	BM
High LTCF accommodation costs	-208	0.015	BM	BM
Lower transition rate to LTCF for all severity levels	562	0.015	BM	BM
Higher transition rate to LTCF for all severity levels	-381	0.015	BM	BM
High accommodation and caregiving costs and high transition rate to LTCF	930	0.014	Do nothing	BM

Natural History of non-AD disease

Stable moderate disease	-3	0.009	BM	BM
AD-like progression	499	-0.007	Do nothing	Do nothing
AD-like progression and AD treatment is partially effective in non-AD patients***	588	-0.090	Do nothing	Do nothing

*Sensitivity analysis was performed at a prevalence rate of 12.7%, except for the scenarios testing high and low AD prevalence values.

**High discontinuation % per year: Community-donepezil 30%, LTCF-donepezil 50%, Community and LTCF memantine 36%; Low discontinuation % per year: Community-donepezil 10%, LTCF-donepezil 40%, Community and LTCF memantine 12%.

***Falsely diagnosed non-AD patients (False positive result) undergo 75% slower AD-like progression, Donepezil is 75% as effective, Memantine is 75% as effective and 50% of the base case value for restarting treatment.

3. REFERENCES

1. Spackman D, Kadiyala S, Neumann PJ, Veenstra D, Sullivan S. Measuring Alzheimer Disease Progression with Transition Probabilities: Estimates from NACC-UDS. *Curr. Alzheimer Res.* 2012;9:1050–8.
2. Neumann PJ, Hermann RC, Kuntz KM, Araki SS, Duff SB, Leon J, et al. Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer’s disease. *Neurology.* 1999;52:1138–45.
3. Beusterien KM, Thomas SK, Gause D, Kimel M, Arcona S, Mirski D. Impact of Rivastigmine Use on the Risk of Nursing Home Placement in a US Sample. *CNS Drugs.* 2004;18:1143–8.
4. Feldman HH, Pirttila T, Dartigues JF, Everitt B, Van Baelen B, Schwalen S, et al. Treatment with galantamine and time to nursing home placement in Alzheimer’s disease patients with and without cerebrovascular disease. *Int. J. Geriatr. Psychiatry.* 2009;24:479–88.
5. Geldmacher DS, Provenzano G, McRae T, Mastey V, Ieni JR. Donepezil is associated with delayed nursing home placement in patients with Alzheimer’s disease. *J. Am. Geriatr. Soc. United States;* 2003;51:937–44.
6. Wattmo C, Wallin AK, Londos E, Minthon L. Risk factors for nursing home placement in Alzheimer’s disease: a longitudinal study of cognition, ADL, service utilization, and cholinesterase inhibitor treatment. *Gerontologist.* United States; 2011;51:17–27.
7. Zhao Y, Kuo T-C, Weir S, Kramer MS, Ash AS. Healthcare costs and utilization for Medicare beneficiaries with Alzheimer’s. *BMC Health Serv. Res.* 2008;8:108.
8. Fillenbaum G, Heyman A, Peterson B, Pieper C, Weiman AL. Frequency and duration of hospitalization of patients with AD based on Medicare data: CERAD XX. *Neurology.* 2000;54:740–3.
9. Gustavsson A, Brinck P, Bergvall N, Kolasa K, Wimo A, Winblad B, et al. Predictors of costs of care in Alzheimer’s disease: a multinational sample of 1222 patients. *Alzheimers. Dement.* 2011;7:318–27.
10. Centers for Medicare & Medicaid Services. Medicare Fee-for-Service Payment Schedule (2009). Available at: <https://www.cms.gov/Medicare/Medicare.html>.
11. Agency for Healthcare Research and Quality. HCUPnet, Healthcare Cost and Utilization Project. 2012.
12. MetLife. Market Survey of Long-Term Care Costs. 2012.
13. Langa KM, Chernew ME, Kabeto MU, Herzog a R, Ofstedal MB, Willis RJ, et al. National estimates of the quantity and cost of informal caregiving for the elderly with dementia. *J. Gen. Intern. Med.* 2001;16:770–8.
14. Bouwman FH, Verwey NA, Klein M, Kok A, Blankenstein MA, Sluimer JD, et al. New Research Criteria for the Diagnosis of Alzheimer’s Disease Applied in a Memory Clinic Population. *Dement. Geriatr. Cogn. Disord.* 2010;30:1–7.